Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo IRENIE
NCT06999980Phase 2Recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in cutaneous melanoma (CM), mucosal melanoma (MM), sponsored by Melanoma Institute Australia. Started Feb 2026; status: recruiting.
02
Drugs
relatlimab
03
Conditions
cutaneous melanoma (CM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT06999980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06999980.